CAR-T(CAR-T)细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T(CAR-T)细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
英文原题:Evidence-Based Recommendations for Nurse Monitoring and Management of Immunotherapy-Induced Cytokine Release Syndrome: A Systematic Review from the Children's Oncology Group.
Evidence-Based Recommendations for Nurse Monitoring and Management of Immunotherapy-Induced Cytokine Release Syndrome: A Systematic Review from the Children's Oncology Group.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
B 前体急性淋巴细胞白血病和 B 细胞淋巴瘤患儿,尤其是复发/难治性疾病患儿,越来越多地被纳入研究免疫疗法的 II 期和 III 期临床试验。这些治疗药物可能与细胞因子释放综合征 (CRS) 的高风险相关,而护士缺乏监测和管理 CRS 患者的标准化指南。本系统评价纳入了 6 项研究和 1 项临床实践指南,这些研究检查了给予CAR-T 细胞疗法或双特异性 T 细胞衔接抗体 blinatumomab 后 CRS 的证据。基于低质量或极低质量证据,制定了 6 条护理实践建议(5 条强,1 条弱):3 条反映输注前监测,1 条侧重于输注期间和输注后监测,3 条涉及护士在 CRS 管理中的作用。
Children with B-precursor acute lymphoblastic leukemia and B-cell lymphoma, particularly those with relapsed or refractory disease, are increasingly enrolled on phase II and phase III clinical trials studying immunotherapies. These therapeutic agents may be associated with a high risk of cytokine release syndrome (CRS), and nurses lack standardized guidelines for monitoring and managing patients with CRS.
Six studies and one clinical practice guideline were included in this systematic review that examined the evidence of CRS following administration of chimeric antigen receptor T-cell therapy or the bi-specific T-cell engager antibody, blinatumomab. Six nursing practice recommendations (five strong, one weak) were developed based on low or very low-quality evidence: three reflect preinfusion monitoring, one focuses on monitoring during and postinfusion, and three pertain to the nurse's role in CRS management.
在 PubMed 查看 → 出版商原文(DOI) 全文 PDF(PMC)· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →
MEMBER ACCOUNT
登录成功会直接打开下一页。